Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligufalimab (AK117) Monotherapy or with Cadonilimab (AK104) in Advanced Tumors
NCT04349969Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Apr 2020
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ligufalimab in solid tumor and lymphoma (2 arms), sponsored by Akeso, Inc. Primary endpoints: Incidence and nature of adverse events (AEs) and Number of participants with a Dose Limiting Toxicity. Started Apr 2020; status: completed.
02
Drugs
ligufalimab
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT04349969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349969.